SEMA3A and prostate cancer: Furthermore, evodiamine, a natural alkaloid, has been shown to inhibit lactate-induced histone lactylation, increase Sema3A expression, and reduce angiogenesis, evodiamine could be a promising candidate for prostate cancer therapy, providing a metabolic-epigenetic approach to overcoming resistance 19.